Aggregation Analysis for Novel, Challenging ADC Conjugates

• Exploration of analytical strategies for aggregation assessment in next-generation ADCs that fall outside the capabilities of standard platform SEC methods
• Integration of SEC, SEC-MALS, and DLS to overcome characterisation challenges associated with highly hydrophobic, aggregation-prone conjugates
• Case study showing how orthogonal aggregation data accelerated candidate down-selection and informed key discovery-stage decisions on drug loading and conjugation strategy

Speakers:

Chaoran Jing

Principal Scientist

Pfizer